Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ardea's Phase III Program For Promising Gout Drug Begins To Take Shape

This article was originally published in The Pink Sheet Daily

Executive Summary

Positive efficacy and clean-as-whistle topline results for unpartnered RDEA594 leave some analysts predicting the drug could become a front-runner in the gout field.
Advertisement

Related Content

AstraZeneca’s Gout Drug Lesinurad Hobbled By Renal Risk
AstraZeneca’s Ardea Acquisition: A Rich Deal Spurred By Phase III Gout Candidate
Krystexxa Cleared For Refractory Gout, Could Reach Patients By Year's End
Krystexxa Cleared For Refractory Gout, Could Reach Patients By Year's End

Topics

Advertisement
UsernamePublicRestriction

Register

PS071796

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel